Astier, Clémence
Ngo, Carine
Colmet-Daage, Léo
Marty, Virginie
Bawa, Olivia
Nicotra, Claudio
Ngo-Camus, Maud
Italiano, Antoine
Massard, Christophe
Scoazec, Jean-Yves
Smolenschi, Cristina
Ducreux, Michel
Hollebecque, Antoine
Postel-Vinay, Sophie
Funding for this research was provided by:
Fondation pour la Recherche Médicale (ECO202206015528)
INSERM - La Ligue Contre le Cancer (ATIP-Avenir 2018)
Article History
Received: 13 October 2023
Accepted: 30 December 2023
First Online: 8 January 2024
Declarations
:
: All patients samples used in this study were stored in a tumor bank at the Gustave Roussy Cancer Campus. Written inform consent for the NGS was obtained from participants, as part of the following studies: MATCH-R (NCT02517892), INCB 54828-202 (NCT02924376), STING (NCT04932525), BoB (NCT03767075) or STARTRK-2 (NCT02568267).
: Informed consent was waived for all retrospective patients and obtained for all prospectively included patients.
: SPV has received research funding from Hoffman La Roche and AstraZeneca for unrelated research projects. As part of the Drug Development Department (DITEP), SPV is principal investigator or sub-investigator of clinical trials from Abbvie, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex Pharmaceuticals, Astra Zeneca, Aveo, Bayer Healthcare Ag, Bbb Technologies Bv, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Chugai Pharmaceutical Co., Clovis Oncology, Daiichi Sankyo, Debiopharm S.A., Eisai, Eli Lilly, Exelixis, Forma, Gamamabs, Genentech, Inc., Glaxosmithkline, H3 Biomedicine, Inc, Hoffmann La Roche Ag, Innate Pharma, Iris Servier, Janssen Cilag, Kyowa Kirin Pharm. Dev., Inc., Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology Nv, Oncoethix, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Pfizer, Pharma Mar, Pierre Fabre, Roche, Sanofi Aventis, Taiho Pharma, Tesaro Inc, and Xencor. SPV has participated to advisory boards for Merck KgaA. The other authors declare no conflict of interest.